Tango Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $62.4M | $42.1M | $36.5M | $24.9M | $37.0M |
| Research and development | $132.2M | $143.9M | $115.2M | $105.9M | $77.6M |
| Operating expenses | $173.7M | $187.7M | $150.7M | $135.9M | $95.2M |
| Operating income | -$111.3M | -$145.6M | -$114.2M | -$111.1M | -$58.2M |
| Pretax income | -$101.6M | -$130.1M | -$101.6M | -$108.1M | -$57.9M |
| Income tax expense | $4,000 | $208,000 | $134,000 | $54,000 | $292,000 |
| Net income | -$101.6M | -$130.3M | -$101.7M | -$108.2M | -$58.2M |
| Balance Sheet | |||||
| Cash and equivalents | $112.3M | $69.5M | $66.4M | $60.0M | $142.7M |
| Current assets | $353.8M | $266.3M | $346.5M | $375.3M | $492.3M |
| Total assets | $398.7M | $316.5M | $402.6M | $436.5M | $500.2M |
| Current liabilities | $21.7M | $38.2M | $45.9M | $55.5M | $40.7M |
| Total liabilities | $52.5M | $117.0M | $149.5M | $187.0M | $155.4M |
| Stockholders' equity | $346.2M | $199.5M | $253.1M | $249.5M | $344.7M |
| Cash Flow Statement | |||||
| Cash from operations | -$138.9M | -$131.5M | -$118.0M | -$109.1M | -$59.5M |
| Depreciation and amortization | $2.3M | $2.5M | $2.4M | $1.6M | $897,000 |
| Stock-based compensation | $26.4M | $28.9M | $19.1M | $14.2M | $7.8M |
| Capital expenditure | $1.0M | $754,000 | $1.5M | $7.7M | $1.8M |
| Free cash flow | -$139.9M | -$132.3M | -$119.5M | -$116.8M | -$61.4M |
| Share repurchases | — | — | $689,000 | — | — |
| Impairments | $0 | $0 | $0 | $0 | $0 |
Shares outstanding 144.6M · Free float 60.6%
Annual filing data through FY ended December 31, 2025; float as of July 15, 2026.